BioPharmSignal logoBioPharmSignal

Biotech News

Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

Beam Therapeutics (BEAM)Beam TherapeuticsEarnings

Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027 U.S. Biologics License Application (BLA) Submission for Risto-cel in Sickle

Related news

BEAMBeam Therapeutics2025-11-04 12:01 EST

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

BEAMBeam Therapeutics2026-05-07 11:00 EST

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

View all latest news

Beam Therapeutics

Base Editing Beam Therapeutics develops precision genetic medicines using base editing, which can change individual DNA bases without creating double-strand breaks. The company integrates editing, delivery and manufacturing capabilities. BEAM-302 BEAM-302 is an in vivo liver-editing candidate for alpha-1 antitrypsin deficiency and is...

Recent company news

BEAMBeam Therapeutics2026-11-04 14:00 EST

Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting

BEAMBeam Therapeutics2026-11-03 12:00 EST

Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

BEAMBeam Therapeutics2026-10-27 11:00 EST

Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress

BEAMBeam Therapeutics2026-10-13 11:00 EST

Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

BEAMBeam Therapeutics2026-09-08 10:00 EST

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

Stock data

Close
25.87 USD
Market cap
2.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States